TACC1 and glioblastoma: The FGFR1-3 receptor inhibitors AZ4547 and BGJ398 were both evaluated for patients with FGFR1-TACC1 and FGFR3-TACC3 fused glioblastomas (NCT028224133 and NCT01975701); however, the results have not yet been published.